VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Petrylak Discusses the Isotope Radium-223

Daniel P. Petrylak, MD
Published: Tuesday, Feb 28, 2012

Daniel P. Petrylak, MD, Professor of Medicine, Co-Leader of Prostate Cancer, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the new isotope agent radium-223 (Alpharadin).

The ALpharadin in SYMptomatic Prostate CAncer (ALSYMPCA) trial that investigated radium-223 for prostate cancer with bone metastases was the first trial to demonstrate an overall survival benefit for an isotopic agent. This agent is set apart by its tolerability when combined with hormonal therapies and chemotherapy.

Radium-233 combines well with docetaxel, something that sets it apart from other approved radiopharmaceuticals. The ALSYMPCA trial investigated the agent in patients that were post – or deemed unfit to receive docetaxel.

Further studies need to be done to determine how to sequence these drugs in a manner that creates a minimum amount of toxicities.

Daniel P. Petrylak, MD, Professor of Medicine, Co-Leader of Prostate Cancer, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the new isotope agent radium-223 (Alpharadin).

The ALpharadin in SYMptomatic Prostate CAncer (ALSYMPCA) trial that investigated radium-223 for prostate cancer with bone metastases was the first trial to demonstrate an overall survival benefit for an isotopic agent. This agent is set apart by its tolerability when combined with hormonal therapies and chemotherapy.

Radium-233 combines well with docetaxel, something that sets it apart from other approved radiopharmaceuticals. The ALSYMPCA trial investigated the agent in patients that were post – or deemed unfit to receive docetaxel.

Further studies need to be done to determine how to sequence these drugs in a manner that creates a minimum amount of toxicities.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x